GSK plc (GSK,GSK.L) has entered an agreement to acquire Nuvalent, Inc. (NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies, for $10.6 billion. The company noted that the acquisition includes three products in lung cancer in a single transaction. GSK will account for the transaction as a business combination.
Luke Miels, CEO, GSK said: "The two lead products are potential best-in-class assets that could launch this year if approved by the FDA and offer significant new treatment options to patients with two forms of non-small cell lung cancer."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.